Evidence map›Paper›PMID 40676860›Full record

ReviewTechnology in cancer research & treatment

Liver Transplantation for Unresectable Colorectal Liver Metastases.

Yash Kadakia, Omar Bushara, Maarouf Hoteit, Peter Abt

Abstract readReview
In one paragraph

Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yash KadakiaDepartment of Surgery, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-3240-2269
Omar BusharaDepartment of Surgery, University of Pennsylvania, Philadelphia, PA, USA.
Maarouf HoteitDepartment of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104.
Peter AbtDepartment of Surgery, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-8682-972X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the third most common malignancy worldwide and a leading cause of cancer-related death. Nearly half of CRC patients develop metastatic disease, with the liver being the most frequent site of metastases. While curative-intent surgical resection remains the gold standard for colorectal liver metastases (CRLM), most patients are initially ineligible for surgery, and recurrence rates remain high. Systemic chemotherapy is the primary treatment for unresectable CRLM, with some patients achieving downstaging to surgical eligibility. Alternative approaches, including immune checkpoint inhibitors for MSI-H/dMMR cancers, hepatic artery infusion pumps, and locoregional therapies, have been explored to improve survival. Liver transplantation (LT) was initially abandoned for CRLM due to poor outcomes, but advancements in surgical techniques, immunosuppression, and donor availability have reignited interest in this approach. With LT becoming an established option for hepatocellular carcinoma and cholangiocarcinoma, its potential role in treating unresectable CRLM is being reconsidered. This review provides the latest evidence on LT for CRLM, including patient selection, outcomes, and future research directions.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsLiver TransplantationHumansTreatment Outcomeadjuvant chemotherapycolorectal cancerliver cancermetastasistransplant

Identifiers

PMID40676860
PMCPMC12276470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.